Clinical features, diagnosis, and natural history of drug-induced liver injury

Seminars in Liver Disease

Volumn 34, Issue 2, 2014, Pages 134-144

  Hayashi, Paul H ^a   Fontana, Robert J ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

acute; chronic; diagnostic tools; hepatotoxicity; histology; prognosis

Indexed keywords

ALKALINE PHOSPHATASE; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; GASTROINTESTINAL AGENT; HALOTHANE; IMMUNOSUPPRESSIVE AGENT; ISONIAZID; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; OXALIPLATIN; TUBERCULOSTATIC AGENT; VALPROIC ACID;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; ASCITES; AUTOIMMUNE HEPATITIS; BRAIN DISEASE; BRAIN EDEMA; CHOLELITHIASIS; CHOLESTATIC HEPATITIS; CLINICAL FEATURE; COMA; COMMON BILE DUCT STONE; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC PROCEDURE; DISEASE COURSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EPSTEIN BARR VIRUS INFECTION; FATIGUE; FATTY LIVER; HEPATITIS E; HEPATOMEGALY; HUMAN; INFLAMMATORY BOWEL DISEASE; JAUNDICE; LACTIC ACIDOSIS; LETHARGY; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER NECROSIS; LIVER REGENERATION; LIVER TOXICITY; LIVER TRANSPLANTATION; LIVER VENOOCCLUSIVE DISEASE; MITOCHONDRIAL TOXICITY; NAUSEA; NONALCOHOLIC FATTY LIVER; PHENOTYPE; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; SYNDROME; TOXIC HEPATITIS; WILSON DISEASE; ANAMNESIS; BIOPSY; BLOOD; COMPLICATION; DIFFERENTIAL DIAGNOSIS; DRUG ADMINISTRATION; DRUG-INDUCED LIVER INJURY; LIVER; LIVER FUNCTION TEST; PATHOLOGY; TIME;

BIOPSY; DIAGNOSIS, DIFFERENTIAL; DRUG ADMINISTRATION SCHEDULE; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER; LIVER FUNCTION TESTS; MEDICAL HISTORY TAKING; TIME FACTORS;

EID: 84901766171     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1375955     Document Type: Article

References (84)

1. Chalasani N., Fontana R. J., Bonkovsky H. L., et al. Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology: 2008; 135 6 1924 1934, e1-e4
2. Andrade R. J., Lucena M. I., Fernández M. C., et al. Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology: 2005; 129 2 512 521 (Pubitemid 41096639)
3. Björnsson E. S., Bergmann O. M., Björnsson H. K., Kvaran R. B., Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology: 2013; 144 7 1419 1425, e1-e3, quiz e19-e20
4. Sgro C., Clinard F., Ouazir K., et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology: 2002; 36 2 451 455 (Pubitemid 34810366)
5. Ostapowicz G., Fontana R. J., Schiodt F. V., et al. U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med: 2002; 137 12 947 954 (Pubitemid 35440240)
6. Watkins P. B. Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther: 2011; 89 6 788 790
7. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf: 2006; 15 4 241 243
8. Björnsson E., Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology: 2005; 42 2 481 489 (Pubitemid 41061102)
9. Polson J., Lee W. M.; American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology: 2005; 41 5 1179 1197 (Pubitemid 40593928)
10. Lee W. M. Drug-induced acute liver failure. Clin Liver Dis: 2013; 17 4 575 586, viii
11. Mindikoglu A. L., Magder L. S., Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl: 2009; 15 7 719 729
12. Danielides I. C., Constantoulakis M., Daikos G. K. Hepatitis on high dose isoniazid: reintroduction of the drug in severe tuberculous meningitis. Am J Gastroenterol: 1983; 78 6 378 380 (Pubitemid 13053686)
13. LiverTox Isoniazid. Available at: http://livertox.nlm.nih.gov/Isoniazid. htm. Accessed June 6, 2013
14. Black M., Mitchell J. R., Zimmerman H. J., Ishak K. G., Epler G. R. Isoniazid-associated hepatitis in 114 patients. Gastroenterology: 1975; 69 2 289 302
15. Harrill A. H., Roach J., Fier I., et al. The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. Clin Pharmacol Ther: 2012; 92 2 214 220
16. LiverTox Heparins. Available at: http://livertox.nlm.nih.gov/Heparin.htm. Accessed October 4, 2013
17. McDonald C., Uy J., Hu W., et al. Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study. AIDS Patient Care STDS: 2012; 26 5 259 264
18. Grant L., Lee W. L., Rockey D. C. Trimethoprim/Sulfamethoxazole hepatotoxicity: Analysis of 31 cases. Hepatology: 2013; 58 (4, Suppl) 382A
19. Blumenthal K. G., Patil S. U., Long A. A. The importance of vancomycin in drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. Allergy Asthma Proc: 2012; 33 2 165 171
20. Fleming P., Marik P. E. The DRESS syndrome: the great clinical mimicker. Pharmacotherapy: 2011; 31 3 332
21. Björnsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand: 2008; 118 5 281 290
22. Björnsson E., Talwalkar J., Treeprasertsuk S., et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology: 2010; 51 6 2040 2048
23. Ghabril M., Bonkovsky H. L., Kum C., et al. US Drug-Induced Liver Injury Network. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol: 2013; 11 5 558, e3
24. Zimmerman H. J. Oncotherapeutic and immunosuppressive agents. In: Zimmerman H. J. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia Lippincott Williams & Wilkins: 1999; 681 687
25. Kalb R. E., Strober B., Weinstein G., Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol: 2009; 60 5 824 837
26. Saag K. G., Teng G. G., Patkar N. M., et al. American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum: 2008; 59 6 762 784 (Pubitemid 351847559)
27. Kremer J. M., Alarcón G. S., Lightfoot R. W. Jr., et al. American College of Rheumatology. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum: 1994; 37 3 316 328 (Pubitemid 24093622)
28. LiverTox Valproate. Available at: http://livertox.nlm.nih.gov/Valproate. htm. Accessed November 5, 2013
29. Zimmerman H. J. Psychotropic and anticonvulsant agents. In: Zimmerman H. J. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia Lippincott Williams & Wilkins: 1999; 504 508
30. Dealberto M. J. Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting. Int Clin Psychopharmacol: 2007; 22 6 330 337
31. Uusimaa J., Hinttala R., Rantala H., et al. Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus. Epilepsia: 2008; 49 6 1038 1045 (Pubitemid 351794000)
32. Angitapalli R., Litwin A. M., Kumar P. R., et al. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer. Oncology: 2009; 76 5 363 368
33. Slade J. H., Alattar M. L., Fogelman D. R., et al. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer: 2009; 8 4 225 230
34. DeLeve L. D., Valla D. C., Garcia-Tsao G.; American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology: 2009; 49 5 1729 1764
35. McDonald G. B., Hinds M. S., Fisher L. D., et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med: 1993; 118 4 255 267 (Pubitemid 23046384)
36. Jones R. J., Lee K. S., Beschorner W. E., et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation: 1987; 44 6 778 783 (Pubitemid 18034278)
37. Danan G., Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol: 1993; 46 11 1323 1330 (Pubitemid 23333873)
38. Benichou C., Danan G., Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol: 1993; 46 11 1331 1336 (Pubitemid 23333874)
39. Maria V. A., Victorino R. M. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology: 1997; 26 3 664 669 (Pubitemid 27392358)
40. Agarwal V. K., McHutchison J. G., Hoofnagle J. H.; Drug-Induced Liver Injury Network. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol: 2010; 8 5 463 470
41. Fontana R. J., Seeff L. B., Andrade R. J., et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology: 2010; 52 2 730 742
42. Barritt A. S. IV, Lee J., Hayashi P. H. Detective work in drug-induced liver injury: sometimes it is all about interviewing the right witness. Clin Gastroenterol Hepatol: 2010; 8 7 635 637
43. Bailey R. L., Gahche J. J., Lentino C. V., et al. Dietary supplement use in the United States, 2003-2006. J Nutr: 2011; 141 2 261 266
44. Navarro V. J., Barnhart H. X., Bonkovsky H. L., et al. The rising burden of herbal and dietary supplement induced hepatotoxicity in the U.S.A. Hepatology: 2013; 58 (4, suppl): 264A
45. Navarro V. J., Bonkovsky H. L., Hwang S. I., Vega M., Barnhart H., Serrano J. Catechins in dietary supplements and hepatotoxicity. Dig Dis Sci: 2013; 58 9 2682 2690
46. Means B., Swan G. E., Jobe J. B., Esposito J. L. An alternative approach to obtaining personal history data. In: Biemeer P. P., Groves R. M., Lyberg L. E., Mathiowetz N. A., Sudman S., eds. Measurement of Errors in Surveys. New York John Wiley and Sons: 1991; 167 183
47. Friedenreich C. M. Improving long-term recall in epidemiologic studies. Epidemiology: 1994; 5 1 1 4 (Pubitemid 24021107)
48. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol: 1990; 11 2 272 276
49. Lammert C., Einarsson S., Saha C., Niklasson A., Bjornsson E., Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology: 2008; 47 6 2003 2009 (Pubitemid 351945567)
50. Chen M., Borlak J., Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology: 2013; 58 1 388 396
51. Food and Drug Administration. Summary of NDA Approvals & Receipts, 1938 to the present. Available at: http://www.fda.gov/AboutFDA/WhatWeDo/History/ ProductRegulation/SummaryofNDAApprovalsReceipts1938tothepresent/default.htm. Accessed March 31, 2013
52. National Library of Medicine LiverTox. Available at: http://www.LiverTox. nih.gov. Accessed March 31, 2013
53. Hoofnagle J. H., Serrano J., Knoben J. E., Navarro V. J. LiverTox: a website on drug-induced liver injury. Hepatology: 2013; 57 3 873 874
54. Yeoman A. D., Westbrook R. H., Al-Chalabi T., et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology: 2009; 50 2 538 545
55. Fernández-Ruiz M., Muñoz-Codoceo C., López-Medrano F., et al. Cytomegalovirus myopericarditis and hepatitis in an immunocompetent adult: successful treatment with oral valganciclovir. Intern Med: 2008; 47 22 1963 1966
56. Cohen J. I., Corey G. R. Cytomegalovirus infection in the normal host. Medicine (Baltimore): 1985; 64 2 100 114 (Pubitemid 15146901)
57. Gupta E., Bhatia V., Choudhary A., Rastogi A., Gupta N. L. Epstein-Barr virus associated acute hepatitis with cross-reacting antibodies to other herpes viruses in immunocompetent patients: report of two cases. J Med Virol: 2013; 85 3 519 523
58. Riviere Marcelin J., Jones J. M., Costello B. A. 41-year-old woman with fever, neutropenia, and elevated transaminase levels. Mayo Clin Proc: 2013; 88 1 113 116
59. Ichai P., Roque Afonso A. M., Sebagh M., et al. Herpes simplex virus-associated acute liver failure: a difficult diagnosis with a poor prognosis. Liver Transpl: 2005; 11 12 1550 1555 (Pubitemid 43072632)
60. Dalton H. R., Fellows H. J., Stableforth W., et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther: 2007; 26 10 1429 1435 (Pubitemid 350045603)
61. Davern T. J., Chalasani N., Fontana R. J., et al. Drug-Induced Liver Injury Network (DILIN). Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology: 2011; 141 5 1665 1672, e1-e9
62. Hoofnagle J. H., Nelson K. E., Purcell R. H. Hepatitis E. N Engl J Med: 2012; 367 13 1237 1244
63. European Association for Study of Liver EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol: 2012; 56 3 671 685
64. Dowling D. Screening for Wilson's disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology: 2009; 50 1 329
65. Maple J. T., Ben-Menachem T., Anderson M. A., et al. ASGE Standards of Practice Committee. The role of endoscopy in the evaluation of suspected choledocholithiasis. Gastrointest Endosc: 2010; 71 1 1 9
66. Yang M. H., Chen T. H., Wang S. E., et al. Biochemical predictors for absence of common bile duct stones in patients undergoing laparoscopic cholecystectomy. Surg Endosc: 2008; 22 7 1620 1624
67. Lindor K. D., Gershwin M. E., Poupon R., Kaplan M., Bergasa N. V., Heathcote E. J.; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology: 2009; 50 1 291 308
68. Chapman R., Fevery J., Kalloo A., et al. American Association for the Study of Liver Diseases. Diagnosis and management of primary sclerosing cholangitis. Hepatology: 2010; 51 2 660 678
69. Farrell G. C. Drug-Induced Liver Disease. Edinburgh, UK Churchill Livingstone: 1994
70. Lewis J. H., Kleiner D. E. Hepatic injury due to drugs, chemicals and toxins. In: Burt A. D., Portmann B. C., Ferrell L. D., eds. MacSween's Pathology of the Liver. Philadelphia, PA Elsevier: 2007
71. Kleiner D. E., Chalasani N. P., Lee W. M., et al. Drug-Induced Liver Injury Network (DILIN). Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology: 2014; 59 2 661 670
72. Björnsson E., Kalaitzakis E., Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther: 2007; 25 12 1411 1421 (Pubitemid 46848886)
73. Katoonizadeh A., Nevens F., Verslype C., Pirenne J., Roskams T. Liver regeneration in acute severe liver impairment: a clinicopathological correlation study. Liver Int: 2006; 26 10 1225 1233 (Pubitemid 44741210)
74. Hennes E. M., Zeniya M., Czaja A. J., et al. International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology: 2008; 48 1 169 176 (Pubitemid 351975541)
75. Czaja A. J. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl: 2007; 13 7 953 955 (Pubitemid 47163184)
76. Ichai P., Duclos-Vallée J. C., Guettier C., et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl: 2007; 13 7 996 1003 (Pubitemid 47163192)
77. Berends M. A., van Oijen M. G., Snoek J., et al. Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy specimens. Arch Dermatol: 2007; 143 12 1515 1519 (Pubitemid 350277766)
78. Rochon J., Protiva P., Seeff L. B., et al. Drug-Induced Liver Injury Network (DILIN). Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology: 2008; 48 4 1175 1183
79. Rockey D. C., Seeff L. B., Rochon J., et al. US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology: 2010; 51 6 2117 2126
80. Fontana R. J., Watkins P. B., Bonkovsky H. L., et al. DILIN Study Group. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf: 2009; 32 1 55 68
81. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology: 2001; 33 1 308 310 (Pubitemid 32016915)
82. Aithal P. G., Day C. P. The natural history of histologically proved drug induced liver disease. Gut: 1999; 44 5 731 735 (Pubitemid 29195925)
83. Björnsson E., Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol: 2009; 50 3 511 517
84. Fontana R. J., Hayashi P. H., Gu J., et al. Idiosyncratic drug induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology: 2014; 56; Mar 26 [Epub ahead of print]